Afatinib 30 mg

Afatinib 30 mg – Precision Treatment for EGFR-Positive Lung Cancer

Afatinib 30 mg is a prescription cancer medicine used to treat non-small cell lung cancer (NSCLC) in patients with mutations in the epidermal growth factor receptor (EGFR) gene. This targeted oral therapy belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It works by blocking signals that help cancer cells grow and multiply.

it is often prescribed as a first-line treatment for patients with advanced EGFR mutation-positive lung cancer. It offers the convenience of oral administration, making it a powerful and patient-friendly alternative to traditional chemotherapy.

How Afatinib 30 mg Works & Its Advantages

This works by irreversibly binding to EGFR and other HER family receptors (HER2, HER4), which are often overactive in lung cancer. By blocking these signals, it slows down or stops the growth of cancerous cells.

Benefits 

.

• Designed for EGFR-positive NSCLC
• Slows disease progression in advanced lung cancer
• Improves survival and quality of life
• Oral tablet—no hospital visits for IV treatment
• Used when patients can’t tolerate higher doses like Afatinib 40 mg

It is commonly used as a dose-adjusted therapy for patients who experienced side effects with the standard 40 mg dose.

Dosage, Administration & Side Effects

Dosage Guidelines:

• It is typically started at 40 mg daily.
• Afatinib 30 mg is used for dose reduction in case of side effects or in elderly/predisposed patients.

Administration:

• Take on an empty stomach (1 hour before or 2 hours after eating).
• Do not crush or break the tablet.

Common Side Effects:

• Diarrhea
• Skin rash
• Mouth sores
• Loss of appetite
• Fatigue

Serious Precautions:

• Monitor for signs of liver toxicity or lung inflammation.
• Regular blood tests are required to check liver function.
• Stay hydrated and inform your doctor of persistent side effects.

Explore Trusted Cancer Therapies

Looking for similar medications to manage NSCLC or other cancers? Browse high-quality anti-cancer treatments including TKIs, hormone therapies, and chemotherapy agents.

Conclusion: Afatinib 30 mg – A Smarter Way to Treat EGFR-Mutated NSCLC

It offers an effective and precise approach to managing EGFR mutation-positive non-small cell lung cancer. It helps extend progression-free survival, especially in patients needing a lower dose due to side effects. When used under expert supervision, it brings new hope to lung cancer patients worldwide.

👉 Order Afatinib 30 mg securely from ShopCPP – Trusted delivery and quality you can rely on.